GNTA logo

GENENTA SCIENCE SPA - ADR

GNTANASDAQ
🏆 #4918 by market capUS Equity
$0.68▲ $0.01 (+1.03%)
After hours · at close
🔔
Track GNTA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.0%
7d▼ 0.6%
14d▼ 22.6%
30d▼ 33.5%
ytd▼ 52.5%
1y▼ 77.4%
🏦Market Cap
$13M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
64
Fair

Trading Snapshot

Day Range
$0.67 – $0.68
52-Week Range
$0.55 – $10.00
Volume
$3.04B
Avg Volume
$2.36B
Shares Outstanding
19.1M
Next Earnings
Dec 2, 2026

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$380,597
P/E Ratio
-1.8
P/S Ratio
0.0x
EPS (TTM)
$-0.29
Dividend Yield
0.00%
Dilution (1yr)
+16.0%

Why Investors Own GNTA

  • ✓High-growth profile — revenue up +42.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 27% gross margin and 6% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

GNTA logo

GENENTA SCIENCE SPA - ADR

GNTA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$6M▼ −37.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$7M▲ +10.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
21.2M▲ +16.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$2M▼ −$7M YoY
StockOtter · stockotter.space

About GENENTA SCIENCE SPA - ADR

Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

🚀
CNBC·2h ago

GENENTA SCIENCE SPA - ADR tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift GNTA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

GENENTA SCIENCE SPA - ADR announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.